ArticleInternational journal of retina and vitreous2025
Outcomes of pars plana vitrectomy for visually significant floaters in Northern Alberta.
Article in International journal of retina and vitreous, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Optimal Treatment of Retinal Vein Occlusion: An Updated Canadian Review and Recommendations.Clinical ophthalmology (Auckland, N.Z.) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundVision degrading mydesposiae (VDM) can have a significant impact on a patient's quality of life. Pars plana vitrectomy (PPV) is a surgical modality used to treat a variety of vitreoretinal diseases and is an accessible treatment option for relief of VDM. This article analyzes outcomes and postoperative complications in a large, local sample of patients who have undergone PPV for symptomatic floaters from a northern Alberta perspective.
methodsA retrospective chart review was conducted at Alberta Retina Consultants in Edmonton, Alberta. Patients who underwent PPV for VDM between 2017 and 2023 were identified. Only cases with floaters due to PVD and asteroid hyalosis were included; cases of prior vitrectomies, scleral buckle surgeries as well as cases of secondary myodesopsiae (i.e. uveitis) were excluded.
resultsA total 452 eyes were identified and following application of exclusion criteria, 410 eyes of 308 patients were included. There were 157 male and 151 female patients with the average age of participants being 68 years (standard deviation (SD) ± 9). Vitrectomy was performed due to symptomatic PVD in 400 eyes (98%) with 10 eyes (2%) being symptomatic due to asteroid hyalosis. There were 181 phakic eyes (44%) and 229 eyes and pseudophakic eyes (56%). There were 26 patients (25.2%) who elected to undergo floaterectomy in the contralateral eye. There was no significant difference in visual acuity noted between preoperative and postoperative periods.
conclusionsThe current study supports PPV as an effective treatment option for symptomatic floaters. There was no statistically significant difference between preoperative and postoperative visual acuity. However, 29.9% of eyes underwent floaterectomy in the contralateral eye, which is in support of patient satisfaction. The observed complication rate was 7.3%, with retinal detachment being the most common complication. Of the 410 eyes, 30 eyes (7.3%) had postoperative complications which included adverse events that were recorded to have occurred between the immediate postoperative period and three years after vitrectomy. Complications include retinal detachment (2.4%), elevated IOP (1.5%), clinically significant cataract requiring surgery (1.5%), vitreous hemorrhage (0.73%), cystoid macular edema (0.98%), dislocated IOL (0.24%), endophthalmitis (0.24%) and epiretinal membrane (0.24). There was a statistically significant difference in visual acuity between preoperative and postoperative periods for eyes with complications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.